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Abstract  25 
Mechanical loading is the primary functional determinant of bone mass and architecture, and 26 
osteocytes play a key role in translating mechanical signals into (re)modelling responses.  27 
Although the precise mechanisms remain unclear, Wnt signalling pathway components, and 28 
the anti-osteogenic canonical Wnt inhibitor Sost/sclerostin in particular, play an important role 29 
in regulating bone’s adaptive response to loading. Increases in loading-engendered strains 30 
down-regulate osteocyte sclerostin expression, whereas reduced strains, as in disuse, are 31 
associated with increased sclerostin production and bone loss. However, while sclerostin up-32 
regulation appears to be necessary for the loss of bone with disuse, the role of sclerostin in the 33 
osteogenic response to loading is more complex. While mice unable to down-regulate 34 
sclerostin do not gain bone with loading, Sost knockout mice have an enhanced osteogenic 35 
response to loading. The molecular mechanisms by which osteocytes sense and transduce 36 
loading-related stimuli into changes in sclerostin expression remain unclear but include several, 37 
potentially interlinked, signalling cascades involving periostin/integrin, prostaglandin, 38 
estrogen receptor, calcium/NO and Igf signalling. Deciphering the mechanisms by which 39 
changes in the mechanical environment regulate sclerostin production may lead to the 40 
development of therapeutic strategies that can reverse the skeletal structural deterioration 41 
characteristic of disuse and age-related osteoporosis and enhance bones’ functional adaptation 42 
to loading. By enhancing the osteogenic potential of the context in which individual therapies 43 
such as sclerostin antibodies act it may become possible to both prevent and reverse the age-44 
related skeletal structural deterioration characteristic of osteoporosis. 45 
46 
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Highlights: 47 
1) Loading-related changes in osteocyte sclerostin expression spatially predict 48 
subsequent osteogenic responses.  49 
2) Acute sclerostin down-regulation is not sufficient for maximal osteogenic responses 50 
to loading. 51 
3) Inability to down-regulate sclerostin precludes functional adaptation to loading, 52 
whereas lack of sclerostin prevents bone loss in disuse. 53 
4) Sclerostin clearly influences the osteogenic context in which loading acts as its 54 
deletion enhances functional adaptation to loading. 55 
 56 
  57 
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Introduction 58 
Mechanical loading is the primary functional determinant of bone mass and architecture [1, 2]. 59 
Loading generates strain (percentage change in dimension) and other mechanically relevant 60 
stimuli (e.g. fluid flow shear stress) throughout the bone tissue and within the osteocyte 61 
canalicular network. Loading levels or distributions which engender strains beyond a habitual 62 
minimum effective strain (MES) trigger bone formation resulting in increased bone mass, 63 
improved bone architecture and thus re-establishment of habitual levels and distribution of 64 
strain [3-5]. Decreased loading, such as occurs during disuse, results in osteoclastic bone 65 
resorption and bone loss in an apparent attempt to also re-establish habitual levels and 66 
distribution of strain. This homeostatic feedback loop, described by Harold Frost as ‘the 67 
mechanostat’ [4], involves the site-specific co-ordinated (re)modelling activity of osteocytes, 68 
osteoblasts and osteoclasts [5].    69 
Osteocytes are embedded in the mineralised matrix and were long thought to have little or no 70 
function, but are now known to play a particularly important role in coordinating local bone 71 
remodelling responses and have recently described as ‘master-regulators’ [6-8]. The Wnt 72 
antagonist Sost/sclerostin is almost exclusively expressed by osteocytes in the adult skeleton 73 
[9], and osteocytes are also an important source of receptor activator of nuclear factor κB ligand 74 
(Rankl) [10], which probably plays a key role in initiating repair in damaged bone; e.g. 75 
apoptosing osteocytes around microcracks secrete Rankl [11]. Canonical Wnt signalling in 76 
osteocytes also regulates bone resorption via the expression of osteoprotogerin (Opg); mice 77 
lacking -catenin in osteocytes have dramatically reduced bone mass due to reduced Opg levels 78 
[12].   79 
Given their location and morphology, with long interlinked dendritic processes forming a 80 
functional syncytium extending to the bone surfaces, osteocytes are ideally suited to sense load-81 
associated strains, including shear strains across their membranes as fluid is displaced through 82 
their canalicular system. Osteocytes are now considered to be the primary mechanosensors 83 
which locally coordinate adaptive (re)modelling responses [13]. The experiment by Skerry et 84 
al [2] that led us to acceptance of this hypothesis was the demonstration of rapid strain 85 
magnitude-related increases in the activity of the metabolism enzyme glucose-6-phosphate 86 
dehydrogenase (G6PD) in osteocytes in the turkey ulna following a short period of loading.    87 
For many years after this, the mechanisms underlying the coordination of adaptive remodelling 88 
responses by osteocytes were largely unknown. Hypothesised mechanisms included direct cell-89 
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cell communication [14, 15] and/or the secretion of paracrine mediators such as prostaglandins 90 
(PG) or insulin-like growth factors (Igf). However, once sclerostin had been shown to be 91 
expressed in osteocytes [9], Robling et al [16] convincingly demonstrated that one potentially 92 
important mechanism by which mechanical loading controls osteocyte activity is by regulating 93 
sclerostin expression. His demonstration that loading the mouse ulna down regulates sclerostin 94 
expression has been reproduced in a variety of experimental loading models [17-23] (Figure 95 
1).  It then led to proposal of the simple model that local, loading-related down-regulation of 96 
osteocyte sclerostin increases bone formation by relieving inhibition of canonical Wnt 97 
signalling in osteoblasts while also, directly or indirectly through regulation of OPG, 98 
supressing the resorptive activity of osteoclasts (Figure 2). The responses of transgenic mice 99 
with altered sclerostin expression to changes in loading strongly support the validity of this 100 
model. However, recent findings of sclerostin-independent changes in bone formation 101 
following loading [24] have demonstrated that this model is somewhat over-simplified. 102 
Furthermore, the mechanisms by which loading-related stimuli initiate this process by down-103 
regulating sclerostin have only been partially explored.  104 
 105 
Loading-related changes in bone mass reflect sclerostin regulation 106 
The model presented in Figure 2 is largely based on the demonstration that the cross-sectional 107 
distribution of strains engendered within loading-responsive regions of mouse long bones 108 
spatially parallel the acute down-regulation of sclerostin protein (within 24 hours following an 109 
episode of loading [18]) and subsequent increases in bone formation. As described above, this 110 
was first demonstrated in the mouse ulna subjected to non-invasive axial loading [16]. Axial 111 
loading of the mouse ulna generates different magnitudes of mechanical strain in the bone’s 112 
proximal, middle and distal regions as well as in different cross-sectional sectors at the same 113 
longitudinal site. Strain magnitudes were found to correlate with both the increase in bone 114 
formation and the down-regulation of sclerostin within these regions. Conversely, the reduction 115 
in strain experienced through tail suspension-induced disuse increased Sost RNA expression in 116 
the mouse tibia. However, protein level analysis of sclerostin expression by 117 
immunohistochemistry following tail suspension did not detect changes in the proportion of 118 
osteocytes stained positive for sclerostin around the level of the tibia/fibula junction [16].  119 
The lack of change in sclerostin expression around the mouse tibia/fibula junction during tail 120 
suspension is potentially consistent with the finding that this region appears to be the least 121 
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affected by disuse, with the most significant bone loss occurring proximal and distal to this 122 
region [25]. In a later study, Moustafa et al [19] mapped site-specific changes in sclerostin 123 
expression in the mouse tibia using immunohistochemistry following unilateral axial loading. 124 
In cross-sections from the highly load-responsive proximal tibia, the increase in bone formation 125 
and decrease in osteocyte sclerostin expression correlated with the mechanical strains predicted 126 
by finite element model analysis. In contrast, in the distal tibia below the tibia/fibula junction, 127 
sclerostin was not down-regulated and bone formation did not increase following loading. In 128 
the same study, disuse following sciatic neurectomy increased sclerostin expression in both the 129 
proximal and distal tibia, and additional loading after disuse significantly reduced sclerostin 130 
expression in both sites, although the magnitude of the effect was greater proximally. Similar 131 
site specificity was also observed in the trabecular compartment of the proximal tibia: loading 132 
reduced sclerostin expression and increased bone gain in the secondary spongiosa, but in the 133 
primary spongiosa no bone formation was observed nor any associated down regulation of 134 
sclerostin expression. These detailed analyses demonstrate that the spatial distribution of bone 135 
loss with disuse and of bone formation following loading closely follow the early changes in 136 
sclerostin expression. However, none of the studies published to date correlating changes in 137 
sclerostin expression with the spatial distribution of bone formation flowing loading have 138 
shown that the two are causally related. The relationship between sclerostin regulation and 139 
bone (re)modelling is clearly complex as both continuous (catabolic) and intermittent 140 
(anabolic) parathyroid hormone (PTH) treatments down-regulate Sost despite having opposite 141 
effects on bone mass [26-28]. 142 
Evidence that the spatial correlation between loading-related sclerostin regulation and changes 143 
in bone (re)modelling may be causal is provided by loading studies using different genetically 144 
modified mouse models. Sclerostin knockout mice do not show bone loss in response to disuse 145 
induced by hind limb unloading [29] or botulinum toxin injection [24], suggesting that 146 
sclerostin up-regulation is necessary for disuse-induced bone loss. To determine whether 147 
sclerostin down-regulation following increased loading is necessary for subsequent bone 148 
formation, transgenic mice harbouring the human SOST gene driven by an 8Kb Dmp1 149 
promoter (SostTg) were generated [20]. Ulna axial loading down-regulates endogenous, but not 150 
human, Sost expression in these mice. Further supporting evidence that sclerostin down-151 
regulation is required for loading-induced bone formation, was the observation that loading 152 
induced significantly greater bone formation in wild type than SostTg mice. These independent 153 
studies specifically test the roles of sclerostin in bone’s adaptation to loading and as such 154 
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provide strong evidence that both loading-related bone gain and disuse-associated bone loss 155 
require changes in sclerostin expression, at least in young mice.  156 
Evidence supporting the potential importance of Sost down-regulation in bones’ osteogenic 157 
response to loading also comes from studies utilising mice with genetic modifications in 158 
mechano-responsive pathways which result in altered Sost regulation following loading. For 159 
example, increased basal sclerostin expression, abrogation of sclerostin down-regulation with 160 
loading and reduced load-related bone formation is observed in periostin knockout (Postn-/-) 161 
mice [22]. Similarly, four point tibial bending of mice lacking osteocytic Igf1 expression does 162 
not result in Sost down-regulation and triggers a diminished osteogenic response to loading 163 
compared with wild type controls [23]. In contrast, deletion of the androgen receptor in male 164 
androgen receptor (AR) knockout mice is associated with greater sclerostin down-regulation 165 
and enhanced bone formation following loading compared with wild type controls [21]. Taken 166 
together, these studies provide examples of situations in which changes in sclerostin regulation 167 
are associated with altered adaptive responses to loading. 168 
 169 
Mechanisms underlying sclerostin down-regulation by loading 170 
The above in vivo studies describing altered basal sclerostin expression and changes in the 171 
load-related regulation of sclerostin in genetically modified mice, while informative, provide 172 
limited insight into the molecular mechanisms by which osteocytes regulate sclerostin 173 
expression. Instead in vitro studies using a variety of model systems have been required to 174 
address this. These studies have shown that the basal rate of sclerostin expression is under both 175 
transcriptional and broader epigenetic control (Figure 3). Its restricted expression in osteocytes 176 
is achieved through an epigenetic mechanism; the SOST promoter is DNA methylated in 177 
osteoblasts but becomes demethylated during the osteoblast to osteocyte transition, allowing 178 
initiation of gene expression [30]. Transcription factors known to bind elements in the 179 
demethylated SOST promoter include the bone-specific transcription factors Runx2 and 180 
Osterix [31, 32]. Bone non-specific transcription factors such as MyoD and C/EBP also bind 181 
the SOST promoter in human Saos-2 cells [31]. The ability of these various factors to regulate 182 
Sost expression is epigenetically determined by histone deacetylase (HDAC) enzymes such as 183 
Sirt1 and HDAC5 [33, 34], and once expressed Sost RNA stability is influenced by micro-184 
RNAs such as miR-218 [35].  185 
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SOST promoter activity is enhanced by Mef2 binding to a distal enhancer element and 186 
inhibition of this binding is one of the mechanisms by which Sost is down-regulated by PTH 187 
[34, 36, 37]. Similar mechanistic studies into Sost regulation by strain have been hindered by 188 
the limited availability of cellular models. Primary osteoblasts do not express readily detectable 189 
levels of Sost until they form mineralised matrix, which precludes their use for in vitro strain 190 
studies. Mouse osteocytic MLO cell lines do not reliably produce readily detectable levels of 191 
Sost [38] and their expression of the constitutively active SV40 antigen [39] impacts 192 
PI3K/AKT signalling, which is a stain-responsive pathway [40]. The more recently developed 193 
IDG-SW3 cell line promises to circumvent this limitation, but these cells only express Sost 194 
after prolonged periods of differentiation [41]. Not surprisingly few osteoblastic cell lines 195 
express detectable Sost. However, rat UMR-106 osteosarcoma cells do respond to strain [40] 196 
and express very high levels of Sost in a manner akin to them having a constitutively active 197 
gene [38], but this makes the physiological relevance of this model questionable. In contrast, 198 
human Saos-2 osteosarcoma cells are also mechanoresponsive, but only confluent cultures 199 
express readily detectable Sost RNA and sclerostin protein [41-43] which is why we have used 200 
this model system. Subjecting subconfluent cultures of Saos-2 cells to in vitro strain by four 201 
point bending increases their proliferation [43, 44], whereas confluent cultures up-regulate 202 
osteocalcin and down-regulate Sost over a time course which parallels that seen in rodent bones 203 
following in vivo mechanical loading [43, 45].  204 
Using the Saos-2 model we initially reported that Sost down-regulation by strain involves 205 
Cox2-initiated PGE2 signalling through an EP4/ERK pathway [45], consistent with a previous 206 
report that selective treatment with an EP4 agonist enhances the osteogenic responses to 207 
mechanical loading in vivo [46]. The importance of this pathway in the mechanical regulation 208 
of Sost expression is further demonstrated by the recent report that Cox inhibition with 209 
carprofen prevents sclerostin down-regulation in the ulnae of mice subjected to axial loading 210 
[47]. Cox2 upregulation in mechanically-stimulated osteoblastic cells is abrogated by 211 
inhibition of nitric oxide (NO)/protein kinase G (PKG) signalling down-stream of calcium 212 
signalling [48]. Inhibition of the NO synthase (Nos) enzyme also abrogates fluid shear-induced 213 
Sost down-regulation in osteoblastic cells [49], whereas long bone derived osteoblastic cells 214 
from AR knockout mice, which show enhanced sclerostin down-regulation in vivo, produced 215 
higher levels of NO when subjected to fluid shear in vitro [21].  216 
AR, NO and PGE2 signalling pathways are all influenced by estrogen receptors (ERs), which 217 
also interact with canonical Wnt pathway components in mechanically strained osteoblastic 218 
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cells [50, 51]. Our group and others have shown that the ERs, particularly ERα, are mediators 219 
of bone’s adaption to loading (as reviewed in [50]). Global deletion of ERα greatly diminishes 220 
cortical osteogenic responses to loading [52] thus we were surprised to observe that blockade 221 
of ERα does not prevent Sost down-regulation by strain in Saos-2 cells, rather ERα inhibition 222 
in vitro or global deletion in vivo reduces basal Sost levels [43]. However, this observation is 223 
consistent with the subsequent demonstration that deletion of ERα in mature osteoblasts and 224 
osteocytes does not impair the adaptive response to axial tibial loading in female mice [53, 54]. 225 
In contrast, ERβ blockade does not alter basal Sost levels, but prevents strain-induced Sost 226 
down-regulation in Saos-2 cells [43]. Although the role of ERβ in bone’s adaptation to loading 227 
has not been extensively investigated, it is worth noting that ERβ enhances Cox2 up-regulation 228 
[55] and ERK activation [56] following mechanical stimulation in different in vitro models.  229 
Both these roles of ERβ are consistent with a down-stream Cox-2/PGE2/ERK pathway 230 
mediating Sost down-regulation following strain, although ERβ may also act down-stream of 231 
PGE2 signalling as PGE2 treatment increases estrogen response element activation in 232 
osteoblastic cells [57]. Interestingly ERβ knockdown prevents periostin up-regulation by 233 
estradiol in periodontal ligament cells [58] and given periostin knockout mice do not show 234 
significant sclerostin down-regulation [22], ERβ’s role in sclerostin regulation may be through 235 
periostin as well as through ERK activation. Activation of ERK could be either up-stream of 236 
periostin action and/or down-stream of its binding to integrin receptors, including integrin αV 237 
[3, 59, 60] and deletion of integrin αV in the osteoblast lineage prevents Sost down-regulation 238 
in the ulnae of mice subjected to axial loading [61]. Integrin αV directly interacts with and 239 
facilitates Igf1/Igf1R signalling [62, 63], which is potentially consistent with the report that 240 
osteocyte Igf1 deletion also abrogates loading-induced Sost down-regulation [23]. Intriguingly, 241 
integrin αv also facilitates opening of connexin (Cx)43 hemichannels and Cx43 facilitates the 242 
release of PGE2, which is involved in the rapid activation of β-catenin in osteoblastic cells 243 
subjected to mechanical stimulation in vitro [64, 65]. However, integrin αV expression is not 244 
required for ERK activation in calvarial osteoblastic cells subjected to fluid shear [61].  245 
To date, no in vivo studies have been published that have systematically investigated the roles 246 
of different mechano-responsive signalling pathways in sclerostin regulation following 247 
loading. The majority of available studies are based on in vitro observations in osteoblastic cell 248 
lines subjected to defined mechanical stimuli which cannot fully replicate the effects of in vivo 249 
loading on the heterogeneous cell populations residing in and on bone. Currently, only 250 
Cox2/prostaglandin signalling has been demonstrated to acutely regulate sclerostin expression 251 
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in vitro, suggesting a direct effect, and to also facilitate sclerostin down-regulation following 252 
loading in vivo. Furthermore, the mechanisms by which unloading results in sclerostin up-253 
regulation have not been investigated and cannot be assumed to be the same as those which 254 
result in its down-regulation following increased loading. Nonetheless, putting the available 255 
jigsaw pieces together it is possible to propose a linear pathway which links early strain-related 256 
signalling events to ultimate down-regulation of Sost expression (Figure 4). The sequence of 257 
events proposed in Figure 4 is potentially consistent with the timing of gene expression changes 258 
seen following loading; Cox2 is up-regulated within 1-2 hours [66] followed by Postn up-259 
regulation around 6 hours [22] and eventually Sost down-regulation 8-24 hours after loading 260 
[47, 67]. However, the direct mechanisms by which loading-related stimuli decrease Sost 261 
promoter activity and/or reduce Sost RNA stability remain unknown and merit further study. 262 
The proposed model is also limited in assuming that all of the reported mediators of Sost down-263 
regulation are involved in osteocytes’ acute and immediate responses to strain. Bones’ ability 264 
to respond to acute changes in loading is context dependent and multiple factors, local and 265 
systemic, are likely to influence the way Sost expression is regulated by loading; e.g. in a bone 266 
which has adapted its mass and architecture to the customary loads placed upon it, osteocytes 267 
and/or adjacent osteoblasts are likely to express factors which may limit or enhance strain-268 
related Sost down-regulation. 269 
 270 
Sclerostin itself influences the osteogenic context in which loading acts 271 
Sclerostin itself is one such modulator of the osteogenic context; e.g. in vitro, its presence 272 
inhibits recruitment of Saos-2 cells to the cell cycle following mechanical strain or Wnt3a 273 
treatment, but not following treatment with estradiol [43, 44]. Sclerostin has also been shown 274 
to reduce proliferation and increase apoptosis in the absence of mechanical stimulation in other 275 
models [68, 69]. In addition, sclerostin has the potential to influence multiple signalling 276 
pathways that regulate various stages of the osteoblast lineage. Reported effects of sclerostin 277 
treatment on osteoblastic cells in vitro include inhibition of differentiation [70-72], inhibition 278 
of mineralisation [71], induction of RANKL expression [73], and promotion of osteocytic 279 
osteolysis [74]. Short term treatment of osteoblastic cells with recombinant sclerostin alters 280 
(predominantly down-regulates) the expression of a large number of genes, many of which are 281 
components of the Wnt signalling pathway [75]. This is consistent with sclerostin acting 282 
primarily as a canonical Wnt signalling inhibitor, although potential interactions with BMP and 283 
12 
 
platelet derived growth factor (PDGF) cascades have also been reported [9, 72]. In the context 284 
of bone’s response to loading, transgenic mice deficient for canonical Wnt co-receptors or the 285 
intra-cellular secondary signalling molecule β-catenin show diminished responses to 286 
mechanical loading [47, 76, 77]. β-catenin is rapidly activated in osteocytes subjected to 287 
mechanical loading, but this response is diminished in osteocytes of mice unable to down-288 
regulate sclerostin [20]. Taken together, these studies provide strong evidence that sclerostin 289 
acts as a canonical Wnt pathway inhibitor and that its down-regulation facilitates activation of 290 
this pathway following loading, but whether sclerostin directly or indirectly modulates other 291 
pathways following loading remains unknown. 292 
 293 
Sclerostin down-regulation is not sufficient for load-related osteogenesis 294 
The findings discussed thus far suggest that altered sclerostin expression is a critical osteocyte 295 
response to changes in mechanical loading and that sclerostin regulation permits/facilitates 296 
both adaptive osteogenesis when loads are increased and net resorption when they are 297 
decreased as in disuse. However, while it is clear that osteocytes, and sclerostin, are important 298 
for mediating bone’s adaptive responses, it is wrong to assume that bone’s responses to disuse 299 
and loading are regulated by the same mechanisms. This was suggested several years ago by a 300 
microarray study which showed that the genes and pathways regulated by loading are not all 301 
the same as those regulated by disuse [67]. Putting it another way; just because a cell or 302 
signalling pathway plays a critical role in the context of disuse, it does not mean that it will 303 
also be as important in regulating the bone formation response following loading. This is 304 
illustrated in an experiment which targeted ablation of osteocytes using diphtheria toxin [78]. 305 
Osteocyte ablated mice do not lose bone during unloading induced by tail suspension, however, 306 
osteocyte ablation does not prevent bone restoration caused by return to normal activity 307 
following a period of disuse. This suggests that either tail suspension induces bone loss through 308 
mechanisms unrelated to loading, such as increased glucocorticoid production [79], or that the 309 
responses of other cells to changes in loading are sufficient for normal bone gain following 310 
loading in the absence of osteocytes (and therefore sclerostin). 311 
This latter interpretation is consistent with the recent report that Sost knockout mice do not lose 312 
bone due to unloading, but still show osteogenic responses to increased loading [24]. In fact, 313 
when loaded so as to generate equivalent strains, Sost-/- mice show greater bone formation than 314 
wild-type controls. Thus, while viable osteocytes able to up-regulate sclerostin expression 315 
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appear to be an absolute requirement for bone loss in disuse, down-regulation of sclerostin 316 
following loading does not appear to be so critical for the subsequent osteogenic response. That 317 
osteocytes are not the only cell involved in the adaptive response to loading should not come 318 
as a surprise given that numerous studies have shown that osteoblast-like cells are also 319 
mechano-sensitive. Well-established responses of osteoblast-like cells to strain include 320 
enhanced osteoblastic differentiation of marrow stromal cells (MSCs) as well as resumption of 321 
proliferation of cortical long bone derived osteoblastic cells [44, 52, 80-82]. Furthermore, the 322 
study which, to the authors’ knowledge, was the first to demonstrate that osteocytes respond 323 
rapidly to changes in mechanical loading showed equally rapid responses (within 6 minutes) 324 
in adjacent periosteal cells [2]. 325 
The ability of osteoblasts to sense and respond to strain in vitro is clearly demonstrated by their 326 
ability to very rapidly enter into the cell cycle after strain exposure in the absence of sclerostin 327 
[18, 43, 44, 52]. In vivo, an increase in the number of osteoblasts on the periosteal surface is 328 
seen within 24 hours following loading [18], although the location and nature of the 329 
proliferative osteoblast population remains undefined. A recent study on the effect of age on 330 
the loading response provides further evidence that down-regulation of sclerostin in osteocytes 331 
does not necessarily translate into an appropriate bone formation response. We hypothesised 332 
that in old mice loading would not down regulate sclerostin, but instead found that loading 333 
down-regulated sclerostin in 19-month-old mice to the same extent as in young (17-week-old) 334 
mice [18], even though the osteogenic response to non-invasive axial tibial loading was lower 335 
in old than in young animals. Interestingly this study showed that in old mice it was the ability 336 
of osteoblasts to proliferate that was compromised; osteoblast progression through the cell 337 
cycle following strain exposure in vitro and the increase in the number of periosteal osteoblasts 338 
following loading in vivo were impaired. These deficiencies in osteoblast function that occur 339 
with age may not only limit bone’s adaptive responses to loading but also the beneficial effect 340 
of sclerostin neutralising therapies [83]. 341 
The finding that osteocytes in tibiae of old mice remain able to sense changes in mechanical 342 
loading and acutely respond by down-regulating Sost has recently been independently 343 
replicated by Holguin et al [84]. In the Holguin study, a single bout of axial tibial loading 344 
effectively down-regulated Sost in 5-month-old as well as 12-month-old and 22-month-old 345 
mice, although the bone formation response was blunted with age. A possible explanation is 346 
that Sost RNA down-regulation is more transient in bones from 22-month-old than 5-month-347 
old mice and others have shown changes in Wnt pathway-related gene transcripts and blunting 348 
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of β-catenin activity in the old [84-86].  Intriguingly, Holguin et al found that while repeated 349 
bouts of loading on subsequent days repeatedly down-regulate Sost in young mice, only the 350 
first bout of loading results in Sost down-regulation in the old. This suggests that old bone cells 351 
become refractory to repeated bouts of increased loading. However, we have recently reported 352 
that prior and concurrent disuse enhances the osteogenic response to repeated bouts of axial 353 
tibial loading in aged mice [87]. Whether this “rescue” of bone’s response to loading in old 354 
mice is associated with the restoration of cells’ ability to down-regulate sclerostin after each 355 
bout of loading needs to be determined. Nonetheless these studies demonstrate bone’s “strain 356 
memory” influences subsequent responsiveness and that this relationship becomes less 357 
effective in the elderly. The relevance of these findings from rodent studies to elderly humans 358 
remains to be established. 359 
 360 
Conclusions 361 
Numerous studies have demonstrated that sclerostin plays a role in the effective working of the 362 
mechanisms associated with regulation of bone mass and architecture in relation to mechanical 363 
loading (the mechanostat). Sclerostin expression increases following unloading with the 364 
consequent inhibition of Wnt signalling and associated bone loss. Down-regulation of 365 
sclerostin is permissive for osteogenesis in response to loading, at least in part by relieving 366 
inhibition of canonical Wnt signalling. This is consistent with the potently osteogenic responses 367 
observed in humans treated with sclerostin-inhibiting antibodies now in advanced stages of 368 
clinical development [88]. However, sclerostin down-regulation in osteocytes is not the only 369 
process linking cellular mechanically-related responses to functional remodelling as evidenced 370 
by mice lacking Sost having an enhanced response to loading. This is consistent with the 371 
emerging narrative that there is not a single linear pathway regulating bone’s adaptive 372 
responses to loading, rather multiple pathways in which osteoblasts as well as osteocytes play 373 
important roles [50, 89, 90]. Elucidating the complex cellular mechanisms involved in 374 
mechano-responsiveness remains important because it could lead to the development of ‘smart’ 375 
novel therapeutic targets able to augment bones’ specific physiological adaptive responses to 376 
loading-engendered stimuli rather than relying on non-specific, and largely ineffective, 377 
therapies to prevent or reverse loss of bone mass. 378 
 379 
 380 
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 605 
Figure 1: Mechanical loading decreases, whereas disuse increases sclerostin expression. 606 
Sclerostin immunolocalisation in tibial cortical bone osteocytes of control limbs subjected to 607 
normal cage activity, limbs subjected to disuse through sciatic neurectomy, and disused limbs 608 
subjected to exogenous osteogenic axial loading. Figure reproduced with permission from 609 
Moustafa et al [19]. Scale bar = 50µm. 610 
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 612 
Figure 2: Simplified model describing sclerostin’s roles in bones’ adaptation to loading-613 
engendered strains. Strains greater than the minimum effective strain (MES, green) are 614 
association with low osteoclast activity and increased osteoblast activity, whereas the low 615 
strains experienced in disuse are associated with reduced osteoblast activity and increased 616 
osteoclast activity. The activity of these effector cells are coordinated by osteocytes at least in 617 
part through sclerostin (red) secretion. In low strain conditions, sclerostin inhibits osteoblast 618 
function and may indirectly promote resorption through Rankl [73]. Strains greater than the 619 
MES down-regulate sclerostin, allowing activation of osteoblasts at least in part through 620 
canonical Wnt signalling, which may indirectly inhibit resorption through Opg expression. 621 
 622 
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 624 
Figure 3: Simplified schematic representation of transcriptional and epigenetic 625 
regulators of basal Sost expression. In osteoblasts, the SOST gene is epigenetically 626 
repressed through DNA methylation (M) and potentially histone acetylation (Ac). HDACs 627 
also fine tune SOST promoter and Mef2-dependant enhancer activity in cells which express 628 
Sost. Transcriptional regulators able to bind the SOST promoter include osteoblast-specific 629 
(Runx2, osterix) and non-bone-specific (MyoD, C/EBP) transcription factors. Once 630 
expressed, Sost RNA stability is influenced by micro-RNAs including miR218.  631 
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 633 
Figure 4: Schematic representation of pathways implicated in sclerostin down-634 
regulation by mechanical stimulation. 1) Strain rapidly activates Ca signalling and down-635 
stream (2) NO/guanylate cyclase (GC)/PKG signalling leading to up-regulation of Cox2, 636 
which also involves ERβ.  Cox2 produces PGE2 (3) which is released at least in part through 637 
Cx43 hemichannels to activate EP receptors including EP4.  EP4 activates ERK (4) 638 
signalling. Strain-induced ERK activation also involves ERβ and ER transcriptional activity 639 
is in turn increased in osteoblastic cells by PGE2.  Activated ERβ can up-regulate periostin 640 
(Postn) expression (5). Periostin acts through integrins (6) including integrin αv, which 641 
interacts with the Igf1 receptor (7).  Responses down-stream of Igf1R include ERα-mediated 642 
activation of AKT (8), however, the mechanisms by which the signalling cascades described 643 
inhibit Sost expression following exposure to strain remain unknown. 644 
